MX2023003245A - Derivados de amina novedosos. - Google Patents

Derivados de amina novedosos.

Info

Publication number
MX2023003245A
MX2023003245A MX2023003245A MX2023003245A MX2023003245A MX 2023003245 A MX2023003245 A MX 2023003245A MX 2023003245 A MX2023003245 A MX 2023003245A MX 2023003245 A MX2023003245 A MX 2023003245A MX 2023003245 A MX2023003245 A MX 2023003245A
Authority
MX
Mexico
Prior art keywords
sup
amine derivative
formula
dyrk
represented
Prior art date
Application number
MX2023003245A
Other languages
English (en)
Inventor
Shingo Tojo
Wataru Kawahata
Yuko ASAMITSU
Daisuke Urabe
Hitoshi Watanabe
Hideki Moriyama
Original Assignee
Sumitomo Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Pharma Co Ltd filed Critical Sumitomo Pharma Co Ltd
Publication of MX2023003245A publication Critical patent/MX2023003245A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención proporciona un derivado de amina que tiene una actividad inhibidora de DYRK y representado por fórmula (I): (ver Fórmula) en donde A1, A2, L1, L2, X, Z, R1 y R4 son como se define en la descripción, o una sal farmacéuticamente aceptable de los mismos.
MX2023003245A 2020-09-18 2021-09-17 Derivados de amina novedosos. MX2023003245A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020157398 2020-09-18
JP2021122893 2021-07-28
PCT/JP2021/034327 WO2022059779A1 (ja) 2020-09-18 2021-09-17 アミン誘導体

Publications (1)

Publication Number Publication Date
MX2023003245A true MX2023003245A (es) 2023-04-11

Family

ID=80776131

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023003245A MX2023003245A (es) 2020-09-18 2021-09-17 Derivados de amina novedosos.

Country Status (11)

Country Link
US (1) US20230365589A1 (es)
EP (1) EP4215534A1 (es)
JP (1) JPWO2022059779A1 (es)
KR (1) KR20230069162A (es)
CN (1) CN116209441A (es)
AU (1) AU2021343770A1 (es)
BR (1) BR112023003807A2 (es)
CA (1) CA3191617A1 (es)
MX (1) MX2023003245A (es)
TW (1) TW202227459A (es)
WO (1) WO2022059779A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2023008470A1 (es) * 2021-07-28 2023-02-02

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0108085A (pt) * 2000-02-07 2003-03-18 Abbott Gmbh & Co Kg Derivados de 2-benzotiazolil uréia e seu uso como inibidores da cinase protéica
EP1679308B1 (en) 2003-10-15 2013-07-24 Ube Industries, Ltd. Novel indazole derivative
JP2010163361A (ja) 2007-04-27 2010-07-29 Dainippon Sumitomo Pharma Co Ltd キノリン誘導体
KR20100010894A (ko) 2008-07-23 2010-02-02 가부시키가이샤 키노파마 Ｄｙｒｋ를 저해하는 화합물을 함유하는 의약 조성물
AU2010219097A1 (en) 2009-01-13 2011-08-04 Glaxo Group Limited Pyrimidinecarboxamide derivatives as inhibitors of SYK kinase
TW201039825A (en) 2009-02-20 2010-11-16 Astrazeneca Ab Cyclopropyl amide derivatives 983
JP2013510824A (ja) * 2009-11-12 2013-03-28 セルビタ エス．エー． セリン／トレオニンキナーゼを調節または制御するための化合物、その調製のための方法、医薬組成物、化合物の使用、方法ならびにセリン／トレオニンキナーゼ調節剤
AU2011323484B2 (en) 2010-11-01 2016-10-06 Portola Pharmaceuticals, Inc. Benzamides and nicotinamides as Syk modulators
UY34200A (es) 2011-07-21 2013-02-28 Bayer Ip Gmbh 3-(fluorovinil)pirazoles y su uso
CN103797002B (zh) * 2011-08-19 2017-02-22 迪亚克森海特公司 Dyrk1抑制剂及其用途
KR20130032847A (ko) 2011-09-23 2013-04-02 주식회사유한양행 이미드를 포함하는 벤조싸이아졸 유도체 또는 그의 염 및 이를 포함하는 약학 조성물
US9127003B2 (en) 2012-07-26 2015-09-08 Glaxo Group Limited 2-(azaindol-2-yl)benzimidazoles as PAD4 inhibitors
HRP20220840T1 (hr) 2013-10-25 2022-10-14 Blueprint Medicines Corporation Inhibitori receptora faktora rasta fibroblasta
GB201401886D0 (en) * 2014-02-04 2014-03-19 Lytix Biopharma As Neurodegenerative therapies
SG11201609830RA (en) 2014-05-23 2016-12-29 Hoffmann La Roche 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are jak inhibitors
WO2016044641A2 (en) 2014-09-17 2016-03-24 Epizyme, Inc. Carm1 inhibitors and uses thereof
CN109206537B (zh) 2018-10-10 2021-04-09 华熙生物科技股份有限公司 一种乙酰化透明质酸钠的制备方法及其应用
WO2021153665A1 (ja) * 2020-01-30 2021-08-05 カルナバイオサイエンス株式会社 新規アルキン誘導体

Also Published As

Publication number Publication date
US20230365589A1 (en) 2023-11-16
TW202227459A (zh) 2022-07-16
KR20230069162A (ko) 2023-05-18
AU2021343770A1 (en) 2023-05-18
CA3191617A1 (en) 2022-03-24
CN116209441A (zh) 2023-06-02
JPWO2022059779A1 (es) 2022-03-24
EP4215534A1 (en) 2023-07-26
BR112023003807A2 (pt) 2023-03-28
WO2022059779A1 (ja) 2022-03-24

Similar Documents

Publication Publication Date Title
IS6902A (is) N-setin heterósýklísk NMDA/NR2B mótlyf sem ekki eru arýl
EA200400981A1 (ru) Новые гетероциклические соединения, активные в качестве ингибиторов бета-лактамаз
TW200642689A (en) Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient
TW200716576A (en) Heterocyclic derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
MX2020009530A (es) Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa.
MX2019012336A (es) Compuestos inhibidores del transportador vesicular de monoaminas 2 (vmat2) y composiciones de los mismos.
MX2022016515A (es) Nuevo inhibidor de la secrecion de acido y uso del mismo.
MX2020002824A (es) Aminas beta-hidroxi heterociclicas y su uso en el tratamiento de la hiperglucemia.
CR20220251A (es) Nuevos derivados de metilquinazolinona
MX2022004451A (es) Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1.
CR20220116A (es) Compuestos heterocíclicos
MXPA05011176A (es) Derivados de carboxamida como agentes antidiabeticos.
MX2021014680A (es) Derivado de benzotriazol.
MX2022004450A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1.
TN2021000025A1 (en) Novel heterocyclic amine derivative and pharmaceutical composition comprising same
MX2023003245A (es) Derivados de amina novedosos.
SG11201810725WA (en) Novel β-lactamase inhibitors
SG11201907945YA (en) Azetidine derivative
MX2021008308A (es) 3compuestos de fenilamidina 3-sustituida, preparacion y uso.
MX2020013729A (es) Compuestos de cianotriazol y usos de los mismos.
PL1845780T3 (pl) Zastosowanie pochodnych metylofenidatu
MXPA05009282A (es) Derivados de anilina sustituidos.
JOP20220082A1 (ar) مشتقات 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4
MX2021003232A (es) Inhibidores de o-glicoproteina-2-acetamido-2-desoxi-3-d-glucopiran osidasa.
CR20230218A (es) Nuevos derivados de indazol acetileno